Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
about
Multiple myelomaCurrent Trends of Renal Impairment in Multiple MyelomaVenous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer AnticoagulantsFirst line vs delayed transplantation in myeloma: Certainties and controversiesNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationVenous and arterial thrombotic risks with thalidomide: evidence and practical guidanceEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesRecent advances in multiple myeloma: a Korean perspectiveOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceThrombosis in multiple myelomaEarly experience with novel immunomodulators for cancer treatmentWhat is the correct philosophy for the treatment of multiple myeloma?Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialImmunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacyUse of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaPhase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myelomaModified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in IndiaPhase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.Novel therapies in multiple myeloma for newly diagnosed nontransplant candidatesLenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma.A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.Anti-angiogenesis therapies: their potential in cancer managementEndothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma.Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses.Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
P2860
Q24655964-EF2D0979-D06F-4CBB-A600-DA42ABD32D68Q26740444-41D7A47E-82DB-491B-A08C-F76020A74362Q26741697-C996368F-30B2-4705-BB21-9A5DA312B60FQ26745957-85F1E370-95FF-4949-B579-C503F9FDB1ADQ26822754-7ECE9C05-979C-4CF3-A6AF-21915AF86466Q26998884-1270E6F1-2935-4C4E-8315-8808E831BEDBQ27002668-5B0B6586-FA72-47BE-9672-9D9EF676FF52Q27008491-1B9D4D3B-3062-4BCE-93AB-06F0D4F933C4Q27026478-16BFFA67-2893-4FB3-AC0B-A0786F6A3636Q28074521-34356557-2703-47EF-B6DD-CDC01441FF39Q28077567-088EBFE2-9732-4431-8E0B-A676659A078AQ28219961-F9A868AD-2B45-420B-AF1D-13D74FA0268BQ28241744-6D027CA2-8253-416C-A43C-354B7175385AQ30366357-2A4A71C0-B312-4CCA-B2AA-64C0EE6042E5Q30433139-BA2D104B-AA92-4B51-922F-DDB0DBF84BD0Q30659342-CFC15F8C-C2D6-4A4D-B1E7-21B67CB7C5EAQ33376918-C7B6A44A-C58E-4FDD-8334-0EEB657DCF87Q33376920-275EC1B9-281D-47B7-9CDB-802F57AE292CQ33383550-453FDB18-C5AD-4603-9ACE-DEB98470BA70Q33389026-385178F0-385D-4520-B9F4-18C19B000A0EQ33401596-6E1596AD-6F17-4214-A19F-E743FD5FB8DBQ33406135-088AAA01-AA52-4EA4-A98B-F98776F8F545Q33408052-5EE1F4B3-6764-42A2-BCB9-C271DEC5B1A3Q33415992-2E95E674-1364-4892-9D23-53F1A40F926EQ33424264-D96D82D8-0CF2-46B2-A019-DDEF5F4D8384Q33429608-E5E37D57-AE4F-4403-BA12-332838718816Q33639796-4E1A2B2B-7D99-47D4-9DBF-A086EE90A68FQ33680252-F8BB9BA1-EC1D-4ECD-B32D-28BBABFCC0AFQ33828783-E6E0FD14-3FC8-4DDC-B3F3-770ED0DC8AABQ33834630-BBF3768A-CA58-4158-BC79-3D2B70CF184AQ33874179-30BC063F-31B6-45F9-B9A4-05A9932C6045Q33942495-B4C7E77D-95E8-4DF4-AAC1-06046D288A4DQ33956056-E6973D3C-B9C2-4528-BBA2-7A98948A9B61Q33967101-BC9ADA81-DA88-4B29-B881-ED0B2CE3454EQ34034447-35271571-DC68-4FA0-BC72-73674F6EE2BFQ34541542-178B00E7-22EE-4E87-8AA8-E7D6CCE746BDQ34586861-74EC4E44-60E0-411F-90E9-01EBB0E28507Q34604658-BCED6872-ED83-4953-9B67-F892090397D9Q34990174-493D9C5F-EBF6-4450-B46C-C59FCB0A95FEQ35153760-96853931-B736-433F-8EAB-3C0BE8982ECB
P2860
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Phase III clinical trial of th ...... rn Cooperative Oncology Group.
@en
Phase III clinical trial of th ...... rn Cooperative Oncology Group.
@nl
type
label
Phase III clinical trial of th ...... rn Cooperative Oncology Group.
@en
Phase III clinical trial of th ...... rn Cooperative Oncology Group.
@nl
prefLabel
Phase III clinical trial of th ...... rn Cooperative Oncology Group.
@en
Phase III clinical trial of th ...... rn Cooperative Oncology Group.
@nl
P2093
P50
P921
P356
P1476
Phase III clinical trial of th ...... rn Cooperative Oncology Group.
@en
P2093
David Vesole
Emily Blood
Philip R Greipp
P304
P356
10.1200/JCO.2005.03.0221
P407
P577
2005-12-19T00:00:00Z